CLINICAL TRIALS
Geographic intelligence for trial site selection, community outreach, and retention, census tract by census tract.
01
Where do underrepresented, trial-eligible populations actually live?
02
What stands between them and a site?
03
Did outreach, enrollment, and retention reach them?
Variate answers all three.
Ranked geographies for sites and community partnerships, based on where unreached eligible populations actually live.
Tract-level maps of who current trial infrastructure can't reach.
Transport-gap flags that predict a missed visit before it's missed.
Outreach, enrollment, retention, and site readiness, measured comparably across geographies and populations, so inclusion is proven, not promised.
200+ federal health and social variables, including tract-level disease prevalence for asthma, COPD, and arthritis (CDC PLACES), fused with social vulnerability, transportation, and health-infrastructure data. Ask a question in plain English; get a map with population counts in about ten seconds. No GIS analyst required.

A real question against real federal data: CDC PLACES, census-tract level. Answered in about ten seconds.
FDA Diversity Action Plans make inclusion a requirement. The shift to community-based and decentralized sites makes it a geography problem. The layer that finds underrepresented populations and proves they were reached barely exists. That's the layer we built.
Live in production · HIPAA-aligned with a signed BAA · Population math done properly, never county averages smeared across empty space · When the model is unsure, it says so, and a human decides.
Read our analysis: Accelerating Clinical Trials →